Day One Biopharmaceuticals Inc’s recently made public that its HEAD OF R&D Blackman Samuel C. unloaded Company’s shares for reported $0.16 million on Apr 18 ’24. In the deal valued at $16.02 per share,10,000 shares were sold. As a result of this transaction, Blackman Samuel C. now holds 1,174,662 shares worth roughly $19.55 million.
Then, Blackman Samuel C. sold 10,000 shares, generating $160,055 in total proceeds. Upon selling the shares at $16.01, the HEAD OF R&D now owns 1,184,662 shares.
Before that, Blackman Samuel C. sold 30,000 shares. Day One Biopharmaceuticals Inc shares valued at $457,314 were divested by the HEAD OF R&D at a price of $15.24 per share. As a result of the transaction, Blackman Samuel C. now holds 1,194,662 shares, worth roughly $19.88 million.
BofA Securities downgraded its Day One Biopharmaceuticals Inc [DAWN] rating to an Underperform from a a Buy in a research note published on April 25, 2023; the price target was decreased to $9 from $34. A number of analysts have revised their coverage, including CapitalOne’s analysts, who began to cover the stock in early February with a ‘”an Overweight”‘ rating. Oppenheimer began covering DAWN with “Perform” recommendation on February 03, 2023. H.C. Wainwright started covering the stock on December 15, 2022. It rated DAWN as “a Buy”.
Price Performance Review of DAWN
On Tuesday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 8.19% to $16.64. Over the last five days, the stock has gained 13.89%. Day One Biopharmaceuticals Inc shares have risen nearly 13.97% since the year began. Nevertheless, the stocks have risen 21.46% over the past one year. While a 52-week high of $17.85 was reached on 03/01/24, a 52-week low of $9.67 was recorded on 01/19/24. SMA at 50 days reached $15.23, while 200 days put it at $13.52. A total of 6.65 million shares were traded, compared to the trading of 0.67 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 15.37, which if violated will result in even more drops to 14.10. On the upside, there is a resistance level at 17.65. A further resistance level may holdings at 18.66. The Relative Strength Index (RSI) on the 14-day chart is 61.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.99, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 19.63%. Stochastics %K at 68.46% indicates the stock is a holding.
The most recent change occurred on December 14, 2022 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
